Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
Tel: 317-276-2000
Website: http://www.lilly.com/
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2321 articles with Eli Lilly and Company
-
Lilly Declares Third-Quarter 2019 Dividend
6/19/2019
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.645 per share on outstanding common stock.
-
The lawsuit was joined by Merck, Eli Lilly and Amgen. The companies claim the Department of Health and Human Services does not have the legal authority to force the companies to comply with the new rule.
-
Clinical Catch-up for June 10-14
6/17/2019
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look. -
Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
6/14/2019
Eli Lilly and Company announced that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head study in patients with active psoriatic arthritis as a late-breaking abstract at the European Congress of Rheumatology in Madrid, Spain on June 15.
-
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association's 79th Scientific Sessions in San Francisco this week.
-
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
6/11/2019
CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor
-
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
6/11/2019
Eli Lilly and Company announced the company will present positive, five-year Phase 3 data for Taltz®.
-
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
6/10/2019
REWIND data showed a consistent effect in people with and without established cardiovascular disease
-
Study Demonstrates Livongo Members More Empowered and Less Distressed in Diabetes Self-Management
6/10/2019
The research findings were presented on June 8, 2019 at the American Diabetes Association's 79th Scientific Sessions held in San Francisco, California.
-
A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.
-
Eli Lilly's Trulicity Significantly Decreases Cardiovascular Events, Still Lags Behind Novo Nordisk
6/10/2019
Despite very positive results, the company’s shares were down 1.5% in premarket trading today. Vamil Divan, an analyst with Credite Suisse, wrote in a note to investors, that results “were fairly consistent across various patient subgroups and are clearly positive” for this class of drug, but “we... -
Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions
6/9/2019
Pivotal phase 3 data in people with type 1 and type 2 diabetes presented at the American Diabetes Association's® 79th Scientific Sessions®
-
Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions®
6/9/2019
Results from several studies of Eli Lilly and Company's investigational dual GIP and GLP-1 receptor agonist, tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes.
-
Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology
6/6/2019
Thirty abstracts will reflect investigations into the treatment of a broad range of rheumatic diseases
-
Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology
6/5/2019
Eighteen abstracts will reveal new insights for the management of moderate-to-severe plaque psoriasis and psoriatic arthritis, as well as the potential treatment of moderate-to-severe atopic dermatitis and alopecia areata
-
Innovent provides Update on the Results of Sintilimab for the Treatment of Extranodal NK/T Cell Lymphoma by Oral Presentation at ASCO
6/5/2019
Innovent Biologics, Inc. announced that the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma by sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, was presented in an oral session at the 55th Annual Meeting of the American Society of Clinical Oncology
-
FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks
6/5/2019
With this approval, Emgality is the only calcitonin gene-related peptide (CGRP) antibody indicated for the preventive treatment of migraine and the treatment of episodic cluster headache
-
The approval marks Emgality as the first calcitonin gene-related peptide (CGRP) antibody to be approved for two distinct headache disorders.
-
FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks
6/4/2019
The U.S. Food and Drug Administration approved Emgality solution for injection for the treatment of episodic cluster headache in adults.
-
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
6/4/2019
The U.S. Food and Drug Administration has accepted the New Drug Application for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release for the treatment of adults with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company announced.